Advertisement
Canada markets open in 7 hours 46 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7327
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    84.01
    +0.44 (+0.53%)
     
  • Bitcoin CAD

    87,839.97
    +162.89 (+0.19%)
     
  • CMC Crypto 200

    1,386.82
    +4.24 (+0.31%)
     
  • GOLD FUTURES

    2,348.20
    +5.70 (+0.24%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,761.25
    +193.75 (+1.10%)
     
  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    38,049.35
    +420.87 (+1.12%)
     
  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.